Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-06), BioRestorative Therapies's 3-1 Month Momentum % is 59.81%.
The industry rank for BioRestorative Therapies's 3-1 Month Momentum % or its related term are showing as below:
FRA:9OF's 3-1 Month Momentum % is ranked better than 95.85% of 1396
companies
in the Biotechnology industry
Industry Median: -7.22
vs FRA:9OF: 59.81
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioRestorative Therapies 3-1 Month Momentum % Related Terms
FRA:9OF vs LIMN, BOLT, TRAW: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, BioRestorative Therapies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a 3-1 Month Momentum % of 59.81% as of Aug. 06, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #58 out of 1396 companies in the Biotechnology industry, placing it in the top 4.2%.
Is BioRestorative Therapies' 3-1 Month Momentum % too high?
BioRestorative Therapies' current 3-1 Month Momentum % is 59.81%. Based on the distribution chart, BioRestorative Therapies ranks #58 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' 3-1 Month Momentum % compare to LIMN and BOLT?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #58 out of 1396 companies for 3-1 Month Momentum %. This places BioRestorative Therapies in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current 3-1 Month Momentum % is 59.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.33, compared to a current price of €0.18 — trading 86.3% below its estimated fair value. The current 3-1 Month Momentum % is 59.81%. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current 3-1 Month Momentum % is 59.81% as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.18 is trading 86.3% below its estimated GF Value™ of €1.33.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
3-1 Month Momentum %: 59.81%
GF Value™: €1.33 vs. price of €0.18 (86.3% below fair value)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score
Get the complete analysis for FRA:9OF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
